eftilagimod alpha

DRUG4 trials

Conditions

Breast CarcinomaHNSCCMetastatic Breast CancerNSCLC

Phase 1

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

WithdrawnNCT04252768

Immutep S.A.S.Metastatic Breast Cancer

Start: 2023-06-30End: 2026-02-28Updated: 2023-03-22

Phase 2

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

CompletedNCT03625323

Immutep S.A.S.HNSCC, NSCLC

Start: 2019-02-21End: 2024-11-25Updated: 2026-04-22

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

CompletedNCT04811027

Immutep S.A.S.HNSCC

Start: 2021-08-27End: 2025-11-05Updated: 2025-12-11

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

TerminatedNCT05747794

Immutep S.A.S.Breast Carcinoma

Start: 2023-05-22End: 2026-06-30Updated: 2026-07-30

Clinical Cancer Research2026-02-17

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.

Journal of Clinical Oncology2025-05-28

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

JTO Clinical and Research Reports2024-08-309 citations

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.

Journal of Clinical Oncology2024-06-012 citations

200P Testing a higher dose (90 mg s.c.) of eftilagimod alpha, a soluble LAG-3 protein in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003

ESMO Open2024-05-01

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Regular and Young Investigator Award Abstracts2023-10-31

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

Journal of Clinical Oncology2023-06-0113 citations

675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Regular and Young Investigator Award Abstracts2022-11-012 citations

578 Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care-therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas. Initial results from INSIGHT–003

Regular and Young Investigator Award Abstracts2022-11-01

A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.

Journal of Clinical Oncology2022-06-0127 citations

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2022-06-014 citations

440 A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC)

Regular and Young Investigator Award Abstracts2021-11-012 citations

359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Regular and Young Investigator Award Abstracts2021-11-011 citations

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

Journal of Clinical Oncology2021-05-2010 citations

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

Journal of Clinical Oncology2021-05-208 citations

790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

2020-11-013 citations

Abstract CT202: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab

Cancer Research2020-08-151 citations

Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

Journal of Clinical Oncology2020-05-2017 citations

eftilagimod alpha

Sponsors

Conditions

Phase 1

Phase 2

Related Papers